Riskpilot← Back to searchSign inGet full accessMediresepti Oy
OYActiveY-tunnus 2620708-5Tammasaarenkatu 3Medical specialists activities · NACE 8622Est. 20140 employeeswww.mediresepti.fi
Revenue 2024
EUR 138K
-5% vs 2023
EBITDA margin
85.3%
-3% vs 2023
Equity ratio
64.6%
Financial strength
Net profit 2024
EUR 37
-21% vs 2023
| Revenue | EUR 138K | -5% |
| EBITDA | EUR 117K | -3% |
| Net profit | EUR 37 | -21% |
| Total assets | EUR 57K | -20% |
| Equity | EUR 37K | +0% |
| Employees | 0 | — |
Legal name
Mediresepti Oy
Y-tunnus number
2620708-5
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
6. toukokuuta 2014
Share capital
EUR 2 500
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Toimitusjohtaja yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on kaikenlaisten terveydenhuollon palvelujen tuottaminen ja tarjoaminen, mukaan lukien lääkäriasema-, yksityisiääkäri- ja vastaavien erikoislääkäripalvelujen tarjoaminen. Yhtiö voi myös harjoittaa ohjelmistojen suunnittelua ja valmistusta, tietojädestelmäpalvelujen tuottamista sekä muuta edellä mainittuihin liittyvää liiketoimintaa, mukaan lukien konsultointia.
Address
Tammasaarenkatu 3
Website
www.mediresepti.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 142 | 142 | 134 | 144 | 138 |
| Staff expenses | — | — | — | −0 | −0 |
| EBITDA | 32 | 97 | 108 | 121 | 117 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | 32 | 97 | 108 | 121 | 117 |
| Net financials | 1 | 1 | 1 | 0 | 0 |
| Profit before tax | 33 | 20 | 22 | 0 | 0 |
| Tax | 6 | 19 | 22 | 0 | 0 |
| Net profit | 27 | 1 | 0 | 0 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 149 | 227 | 240 | 72 | 57 |
| Equity | 36 | 37 | 37 | 37 | 37 |
| Long-term debt | — | — | — | 0 | 0 |
| Short-term debt | 113 | 190 | 203 | 35 | 20 |
| Total debt | 113 | 190 | 203 | 35 | 20 |
EBITDA margin
85.3%
This company
15.8%
Market median
+440% vs market
20202024
Equity ratio
64.6%
This company
38.2%
Market median
+69% vs market
20202024
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
2.39×
This company
1.12×
Market median
+113% vs market
20202024
Debt / equity
0.55×
This company
0.62×
Market median
+11% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TE Chief Executive Officer | Chief Executive Officer | 2014 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2014 | |
| Chairperson | 2014 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MC-Group Oy
Mediresepti Oy Board members of Mediresepti Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tommi Eerikki Salaspuro | Chief Executive Officer | 0 companies |
| Tommi Kaleva Rissanen | Board of Directors | 0 companies |
| Ville Juhana Salaspuro | Chairperson | 0 companies |